NADPH oxidase 1 is a novel pharmacological target for the development of an antiplatelet drug without bleeding side effects by Vara, D et al.
The FASEB Journal. 2020;34:13959–13977.    | 13959wileyonlinelibrary.com/journal/fsb2
Received: 1 May 2020 | Revised: 1 August 2020 | Accepted: 7 August 2020
DOI: 10.1096/fj.202001086RRR  
R E S E A R C H  A R T I C L E
NADPH oxidase 1 is a novel pharmacological target for the 
development of an antiplatelet drug without bleeding side effects
Dina Vara1 |   Anuradha Tarafdar1 |   Meral Celikag1 |   Daniela Patinha1 |    
Christina E. Gulacsy2 |   Ellie Hounslea2 |   Zach Warren1 |   Barbara Ferreira1 |    
Maarten P. Koeners1 |   Lorenzo Caggiano2 |   Giordano Pula3
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology
Lorenzo Caggiano and Giordano Pula contributed equally to this study.  
Abbreviations: 2APT, 2-acetylphenothiazine; ANOVA, analysis of variance; CAD, coronary artery disease; CGD, granulomatous disease; CMH, 
1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine; DETC, diethyldithiocarbamate; DiOC6, 3,3′-Dihexyloxacarbocyanine Iodide; DMSO, 
dimethyl sulfoxide; EPR, electron paramagnetic resonance; FeCl3, ferric chloride; FITC, fluorescein isothiocyanate; NOXs, NADPH oxidases; PAD, 
peripheral artery disease; PE, phycoerythrin; PGE1, prostaglandin E1; PPACK, D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone; PRP, platelet-rich 
plasma; ROS, reactive oxygen species; TRITC, tetramethylrhodamine.
1Institute of Biomedical and Clinical 
Science, University of Exeter Medical 
School, Exeter, UK
2Department of Pharmacy and 
Pharmacology, University of Bath, Bath, 
UK
3Institute of Clinical Chemistry and 
Laboratory Medicine, University Medical 




Giordano Pula, Institute of Clinical 
Chemistry and Laboratory Medicine, 




British Heart Foundation (BHF), 
Grant/Award Number: FS/14/2/30630, 
PG/15/40/31522 and PG/15/68/31717; 
Alzheimer's Research UK (ARUK), Grant/
Award Number: ARUK-PG2017A-3; 
British Heart Foundation (BHF)
Abstract
Growing evidence supports a central role of NADPH oxidases (NOXs) in the regula-
tion of platelets, which are circulating cells involved in both hemostasis and throm-
bosis. Here, the use of Nox1−/− and Nox1+/+ mice as experimental models of human 
responses demonstrated a critical role of NOX1 in collagen-dependent platelet ac-
tivation and pathological arterial thrombosis, as tested in vivo by carotid occlusion 
assays. In contrast, NOX1 does not affect platelet responses to thrombin and normal 
hemostasis, as assayed in tail bleeding experiments. Therefore, as NOX1 inhibitors 
are likely to have antiplatelet effects without associated bleeding risks, the NOX1-
selective inhibitor 2-acetylphenothiazine (2APT) and a series of its derivatives gen-
erated to increase inhibitory potency and drug bioavailability were tested. Among 
the 2APT derivatives, 1-(10H-phenothiazin-2-yl)vinyl tert-butyl carbonate (2APT-
D6) was selected for its high potency. Both 2APT and 2APT-D6 inhibited collagen- 
dependent platelet aggregation, adhesion, thrombus formation, superoxide anion 
generation, and surface activation marker expression, while responses to thrombin or 
adhesion to fibrinogen were not affected. In vivo administration of 2APT or 2APT-
D6 led to the inhibition of mouse platelet aggregation, oxygen radical output, and 
thrombus formation, and carotid occlusion, while tail hemostasis was unaffected. 
Differently to in vitro experiments, 2APT-D6 and 2APT displayed similar potency 
in vivo. In summary, NOX1 inhibition with 2APT or its derivative 2APT-D6 is a  
viable strategy to control collagen-induced platelet activation and reduce thrombosis 
without deleterious effects on hemostasis. These compounds should, therefore, be 
considered for the development of novel antiplatelet drugs to fight cardiovascular 
diseases in humans.
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1 |  INTRODUCTION
Platelets are anucleated cells released in the bloodstream by 
their progenitors residing in the bone marrow, the megakary-
ocytes. Platelets are responsible for the initiation of hemo-
stasis, which is the interruption of bleeding upon vascular 
damage. Hemostasis consists of primary hemostasis, which is 
the activation, adhesion, and accumulation of platelets at the 
site of injury in the form of thrombi, and secondary hemosta-
sis, which is the activation of the coagulation cascade leading 
to the deposition of fibrin within thrombi to form blood clots. 
Primary and secondary hemostasis are tightly connected, 
with platelet activation during primary hemostasis facilitat-
ing the initiation of coagulation, and secondary hemostasis 
driving platelet activation via the generation of thrombin as 
one of the main products of the coagulation cascade. The 
distinction between primary and secondary hemostasis was 
made to help our understanding of this phenomenon, but has 
no temporal or spatial relevance, as these two events occur 
within the same microenvironment with overlapping kinetics. 
The unwanted blood vessel occlusion due to either platelet or 
coagulation activation is known as thrombosis. Thrombosis 
is responsible for important vascular diseases such as stroke, 
coronary artery disease (CAD), and peripheral artery disease 
(PAD). Antithrombotics can be divided into antiplatelet or 
anticoagulant drugs, depending on whether they target pri-
mary or secondary hemostasis, respectively. Oxidative stress 
is the dysregulated generation of reactive oxygen species 
(ROS) and has been shown to cause platelet hyperactiv-
ity leading to thrombosis.1-4 NADPH oxidases (NOXs) are 
important sources of ROS in platelets5-7 and their function 
promotes platelet activation.8,9 NOXs are a family of multim-
eric plasma membrane complexes generating the majority of 
non-mitochondrial ROS in mammalian cells. Each complex 
consists of a catalytic subunit and a number of regulatory 
subunits responsible for the maturation, stabilization, haem 
incorporation, and translocation to the cell membrane of the 
enzymatically functional complex. All NOX family members 
act as catalysts for the transfer of electrons from NADPH to 
molecular oxygen to form ROS. NOX1, NOX2, NOX3, and 
NOX5 generate superoxide anion, while NOX4, DUOX1, 
and DUOX2 release hydrogen peroxide. Although platelet 
NOX2 has been investigated,4 the expression of NOX1 in 
human platelets has only been described relatively recently.10 
Despite the established importance of NOXs in the molecu-
lar mechanisms leading to platelet activation,8,9,11 the exact 
role of different NOX isoenzymes, and the molecular mecha-
nism linking NOX activity to platelet regulation remains un-
certain.9,12-14 Nonetheless, a convincing amount of evidence 
suggests that the enzymatic activity of NOXs plays a signifi-
cant role in promoting platelet responses.15 Therefore, several 
pharmacological tools for the inhibition of NOXs that have 
been recently developed and described may have import-
ant platelet modulatory effects.10,16-21 If that is confirmed, 
NOX inhibitors may become novel antiplatelet drugs to add 
to existing cardiovascular treatments. They may be partic-
ularly useful for vascular complications caused by platelet 
hyperactivity, as observed in diabetes, metabolic syndrome, 
hypertension, and atherosclerosis.1,5,6,22 Interestingly, the ef-
ficacy of NOX inhibition in patients displaying resistance to 
traditional antiplatelet drugs has been described,23 suggesting 
that targeting NOXs may become a valid alternative to fight 
thrombosis.11
The work from our and other laboratories highlighted 
the central role of NOX1 in the signal transduction of col-
lagen-dependent platelet activation.13,24 Recently, we uti-
lized selective agonists and a novel electron paramagnetic 
resonance-based technique to show that the signaling of the 
collagen receptor GPVI requires NOX1.14 These results are 
paralleled by a recent study showing that NOX2 is dispens-
able for GPVI-dependent activation of platelets ex vivo and 
the carotid thrombosis induced by photochemical injury in 
vivo.12 This recent evidence is in contrast with previous stud-
ies indicating NOX2 as critical for the activation of plate-
lets by collagen and for the development of thrombosis in 
vivo.9 Although differences in the methodologies may partly 
explain this discrepancy (eg, ferric chloride vs photochemi-
cal vascular injury in vivo), the exact roles of different NOX 
family members in the redox-dependent regulation of plate-
lets remain to be fully explained. Other aspects that remain 
to be elucidated are the mechanisms of activation of NOXs 
in platelets and the downstream signaling that they activate. 
Currently, a role for the small GTPase Rac1 has been pro-
posed for the activation of NOXs in platelets,25,26 while the 
most likely mechanism of signal transduction that they trigger 
involves the oxidative inactivation of the protein phosphatase 
SHP2 resulting in the potentiation of the protein kinase cas-
cade activated by GPVI in response to collagen.27,28
In this study, we aimed to test the effect of the NOX1 
inhibitor 2-acetylphenothiazine (2APT) and a series of its 
derivatives for their effect on platelets in vitro and for their 
ability to be absorbed via oral administration in mice and 
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affect platelet responses ex vivo or hemostasis/thrombosis 
responses in vivo. 2APT derivatives were designed to re-
solve the two main weaknesses of 2APT: (1) small concen-
tration window at which the drug is selective for NOX1 (ie, 
no effect on NOX1 below 200nM and inhibition of other 
NOXs above 3 μM)21; (2) undesirable hydrophobic profile.
2 |  METHODS
2.1 | 2APT derivative synthesis
Detailed synthesis and purity control procedures are de-
scribed in the Methods Supplement, while compound struc-
tures are described in Figure 1.
2.2 | Mouse maintenance, murine blood 
collection, and platelet preparation
Previously described Nox1−/−29 and Nox2−/−30 mice were 
utilized for this study. Mouse maintenance was per-
formed according to the local ethical approval (University 
of Exeter) and Home Office licensing for Scientific 
Procedures (PPL30/3348). Although only 12-weeks-old 
female mice were utilized for experiments throughout this 
manuscript, initial characterization experiments showed 
that for all the mouse strains used in this project, plate-
let aggregation responses in male and female animals are 
comparable (ie, no sexual difference). For washed plate-
lets, sodium citrate was used as an anticoagulant (0.5% 
w/v). Platelet-rich plasma (PRP) was separated from whole 
blood by centrifugation (180×  g, 15  minutes) and plate-
lets were separated from PRP by a second centrifugation 
step (600×  g, 10  minutes) in the presence of prostaglan-
din E1 (PGE1, 40  ng/mL) and indomethacin (10  μM). 
Platelets were resuspended in modified Tyrode's buffer at 
a density of 2 × 108 platelets/mL throughout the study. For 
whole blood analyses (eg, thrombus formation), heparin- 
and D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone 
(PPACK)-anticoagulated whole blood were used (5 unit/mL 
and 25 μM, respectively).
2.3 | Platelet aggregation by turbidimetry
Platelets resuspended in modified Tyrode's buffer at a density 
of 2 × 108 platelets/mL were stimulated using a Chrono-Log 
490 4 + 4 aggregometer (Havertown, US). Aggregation was 
induced with 0.1 unit/mL of human thrombin or 3 µg/mL of 
Horm collagen. Absorbance was measured for 10  minutes 
and expressed as % change in absorbance.
2.4 | Carotid occlusion model
The procedure has been performed as described previously 
described.31,32 Briefly, anesthesia was induced with 4% isoflu-
rane and maintained at 1.5%-2% isoflurane. The carotid artery 
was surgically exposed and fitted with a miniature transonic 
flow probe (Transonic Systems Inc TS420, USA). The probe 
was linked to a CED Micro1401 acquisition unit (Cambridge 
Electronic Design Limited, UK) via a flowmeter (Transonic 
Systems Inc, USA). Ferric chloride (FeCl3, 10% w/v) was ap-
plied topically to the exposed artery via a piece of filter paper 
(1 × 1.5 mm) to induce thrombus formation. After 5 minutes, 
the filter paper was removed, while blood flow was continu-
ously recorded until cessation (ie, occlusion) or alternatively 
up to 40 minutes in occlusion-free mice. Data were acquired 
using Spike2 (Cambridge Electronic Design Limited, UK) 
software. Time to occlusion after the FeCl3 challenge was 
analyzed and utilized as a measure of susceptibility to throm-
bosis. Hematoxylin staining of explanted carotid sections 
after ferric chloride treatment was used to confirm occlusion.
2.5 | Tail tip transection assay
Mice were anesthetized by the inhalation of 4% isoflurane 
and continuously maintained at 1.5% isoflurane. The animals 
were placed in the prone position and a 3-mm segment of the 
tail was amputated with a scalpel. The tail was immediately 
immersed in pre-warmed isotonic saline at 37°C. The bleed-
ing time was measured manually.
2.6 | Electron paramagnetic resonance 
(EPR)
As described in our previous study,14 prior to adding stimuli, 
200  µM 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-
pyrrolidine (CMH), 5  µM diethyldithiocarbamate (DETC), 
and 25 µM deferoxamine were added to platelets (density ad-
justed to 2 × 108 platelets/mL) with continuous stirring. After 
1 minute, stimuli were delivered and 10 minutes later 50 μL 
of platelet-free supernatant was collected and read using an 
E-scan (Noxygen, Germany). EPR spectra were recorded 
using the following EPR settings: center field 3490 G, field 
sweep 60 G, modulation amplitude 2 G, sweep time 10 sec-
onds, number of scans 10, microwave frequency 9.39 GHz. 
A calibration curve was obtained from standard CM● diluted 
to concentrations of 0, 0.3, 1, 3, 10, and 30 µM and utilized to 
estimate the CM● concentration in the samples as described 
in Figure S1. The CMH oxidation rate was obtained using the 
following formula: CMH oxidation rate = [CM●] × Volume/ 
(Platelet density × Volume × Time).
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2.7 | Human blood collection and platelet 
preparation
Procedures utilizing human blood conform to the principles 
outlined in the Declaration of Helsinki. Volunteers were 
male and female between ages 25 and 65, with no diagnosis 
of cardiovascular disease, diabetes or cancer. Volunteers 
on antiplatelet, anticoagulant, and anti-inflammatory drugs 
were excluded from the study. Human blood was drawn 
from the median cubital vein venepuncture following the 
F I G U R E  1  2APT derivative structures and calculated partition coefficients (cLogP). The cLogP values were calculated using the ChemDraw 
software package from Alfasoft™ (Goteborg, Sweden)
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Royal Devon and Exeter NHS Foundation Trust Code of 
Ethics and Research Conduct and under National Research 
Ethics Service South West—Central Bristol approval (Rec. 
n. 14/SW/1089). Informed written consent was given prior 
to the inclusion of participants in the study. Sodium cit-
rate was used as an anticoagulant (0.5% w/v). Platelet-rich 
plasma (PRP) was separated from whole blood by centrifu-
gation (250× g, 17 minutes) and platelets were separated 
from PRP by a second centrifugation step (500× g, 10 min-
utes) in the presence of prostaglandin E1 (PGE1, 40 ng/mL) 
and indomethacin (10 μM). For whole blood analyses (eg, 
thrombus formation), heparin- and PPACK-anticoagulated 
whole blood was used.
2.8 | Platelet static adhesion
Platelets at a density of 2  ×  107 platelets/mL were treated 
with NOX inhibitors for 10 minutes and then seeded on colla-
gen- or fibrinogen-coated coverslips for 30 minutes at 37°C. 
After the removal of non-adhering cells, platelets were fixed 
with 4% paraformaldehyde for 10 minutes. After permeabi-
lization with 0.1% Triton X/PBS, 10 µM tetramethylrhoda-
mine (TRITC)-conjugated phalloidin was utilized to stain 
the actin cytoskeleton. Quantification of platelet adhesion 
was obtained by LED fluorescence microscopy (EVOS Fl) 
and image analysis using ImageJ 1.47v (Wayne Rasband, 
National Institute of Health, USA).
2.9 | Thrombus formation under 
physiological flow assay
In order to test collagen-dependent platelet activation and 
thrombus formation in physiological flow conditions, a 
flow assay was performed in anticoagulated blood as previ-
ously described.33 Human or mouse blood was anticoagu-
lated with 5 u/mL of heparin and 40 µM PPACK and labeled 
with 1  μM 3,3′-Dihexyloxacarbocyanine Iodide (DiOC6) 
for 10 minutes. Ibidi Vena8 Fluoro + flow microchips and 
a Cellix Exigo pump were utilized to analyze thrombus for-
mation in whole blood underflow. Microchips were coated 
with Horm collagen (0.1 μg/mL). Thrombus formation was 
visualized by fluorescence microscopy at a shear rate of 
1000  sec−1. Surface coverage was analyzed using ImageJ 
1.47v (Wayne Rasband, National Institute of Health, USA).
2.10 | Platelet activation measured by 
flow cytometry
As previously described,34 washed human platelets were 
stimulated with 1  unit/mL of thrombin or 5  μg/mL of 
cross-linked collagen-related peptide (CRP-XL) and fixed in 
1% w/v paraformaldehyde for 30  minutes. After diluting 1 
in 10 in modified Tyrode's buffer, fluorescein isothiocyanate 
(FITC)-conjugated anti-activated integrin αIIbβ3 (PAC-1, 
#340507, BD Biosciences) or phycoerythrin (PE)-conjugated 
anti-P-selectin (#561921, BD Biosciences) was used to stain 
platelets and fluorescence staining was assessed using a 
FACS Aria III flow cytometer (BD Biosciences).
2.11 | Pharmacological treatment of mice
Drug administration was obtained by mixing either 2APT or 
2APT-D6 (in 2% v/v dimethyl sulfoxide (DMSO)) with solid 
food to reach a daily dose of 20, 60 or 200 mg of medication per 
kg of mouse body weight. About 2% v/v DMSO vehicle solution 
was used as a negative control. All in vivo studies are in accord-
ance with ARRIVE guidelines and were performed accord-
ing to local ethical approval (University of Exeter) and Home 
Office licensing for Scientific Procedures (PPL30/3348). All 
animal procedures conformed to the guidelines from Directive 
2010/63/EU of the European Parliament on the protection of 
animals used for scientific purposes. Euthanasia was obtained 
by neck dislocation under 1.5%-2% isoflurane anesthesia.
2.12 | Liquid chromatography-mass 
spectrometry to detect 2APT and derivatives 
in vivo
Organ homogenates or plasma were precleared by acetonitrile 
1:1 precipitation. The QTOF-UHPLC analysis was conducted 
using a MaXis HD quadrupole electrospray time-of-flight (ESI-
QTOF) mass spectrometer (Bruker Daltonik GmbH, Bremen, 
Germany), operated in ESI positive-ion mode. The capillary 
voltage was set to 4500 V, nebulizing gas at 4 bar, drying gas at 
12 L/min at a drying temperature of 220°C. Mobile phases A 
and B consisted of 0.1% v/v formic acid in water and 0.1% v/v 
formic acid in acetonitrile, respectively. Gradient elution was 
carried out with 10% mobile phase B for 2 minutes followed 
by a linear gradient to 99% B until 8 minutes, then returned to 
10% B in 12 minutes total run time. The mass calibrant solu-
tion consisted of three parts of 1 M NaOH to 97 parts of 50:50 
water:isopropanol with 0.2% formic acid. 2APT was detected 
as [M]+ and [M + H]+ ions at 241.0556 and 242.0634 m/z. 
Data processing was performed using the Data Analysis soft-
ware version 4.3 (Bruker Daltonik GmbH, Bremen, Germany).
2.13 | Statistical analysis
For dual comparisons of normal/homoscedastic data, statis-
tical analysis was performed by one-tailed unpaired t-tests. 
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Dual comparisons of non-normal/non-homoscedastic data 
were analyzed by one-tailed non-parametric Mann-Whitney 
test. One-way analysis of variance (ANOVA) with Bonferroni 
post-test was used for multiple comparison tests of normal/ho-
moscedastic data. Data normality and homoscedasticity were 
tested with Shapiro-Wilk and Bartlett's tests, respectively. 
F I G U R E  2  NOX1 positively regulates collagen-dependent activation of platelets and facilitates carotid occlusion in vivo. Platelets were 
isolated from NOX1−/−, NOX2−/−, and wild-type mice (WT, C57BL6/J) and resuspended at 2 × 108 cells/mL. Aggregation was obtained with 3 µg/
mL of collagen (A) or 0.1 unit/mL of thrombin (B) and measured for up to 10 minutes. Traces shown on the left are representative of 4 independent 
experiments, while quantitative analysis is shown on the right. NOX1−/−, NOX2−/−, and WT mice were also tested in a ferric chloride-induced 
carotid occlusion assay. The time required for complete occlusion from 6 animals is displayed in (C), while hematoxylin staining of explanted 
carotid sections after ferric chloride treatment is shown in the insert. The hemostatic response was assessed with a tail tip transection assay and the 
time necessary for complete interruption of the bleeding from 9 animals per genotype is shown in (D). Statistical analysis was performed by one-
way ANOVA with Bonferroni post-test (* for P < .05, ** for P < .01, *** for P < .001, ns for non-significant)
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Static adhesion experiments were normalized and analyzed 
by one-sample t-test vs 100% for the untreated condition. The 
statistical software package GraphPad Prism Version 8.1.0 
for Windows 64 bit was used. Results were expressed as the 
mean ± standard error (SEM). Differences were considered 
significant at P value < .05 (*), .01 (**) or .001 (***).
F I G U R E  3  2APT selectively inhibits 
NOX1 in superoxide anion formation 
assays. Platelets were isolated from 
NOX1−/− and WT mice (C57BL6/J) and 
resuspended at 2 × 108 cells/mL. Superoxide 
anion output was measured by EPR 
following platelet activation with 3 µg/mL 
of collagen (A) or 0.1 unit/mL of thrombin 
(B) and measured for 10 minutes. Platelets 
were pretreated with 0, 1 or 10 µM 2APT 
for 10 minutes. The amount of oxidized 
CMH was quantified as described in the 
Methods and in Figure S1 and expressed 
as attomoles of CMH oxidized per platelet 
per minute. Data from 4 independent 
experiments are shown, while representative 
EPR traces are shown in the upper panels. 
Statistical analysis was performed by one-
way ANOVA with Bonferroni post-test 
(* for P < .05, ** for P < .01, *** for 
P < .001, ns for non-significant)
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3 |  RESULTS
Thrombin- and collagen-induced aggregation experiments 
using platelets from NOX1−/− and NOX2−/− mice showed 
that collagen-induced aggregation is significantly inhib-
ited in NOX1−/− (Figure  2A), while thrombin-induced 
aggregation is significantly reduced in NOX2−/− platelets 
(Figure 2B). Carotid occlusion (Figure 2C, and representa-
tive traces in Figure S2) and tail tip transection bleeding time 
(Figure 2D) showed that NOX1−/− mice have significantly 
delayed carotid occlusion compared to wild-type mice, while 
tail bleeding is not affected. The response of NOX2−/− mice 
F I G U R E  4  2APT selectively inhibits 
platelet aggregation in a NOX1-dependent 
manner. Mouse platelet aggregation was 
stimulated with 3 µg/mL of collagen 
(A) or 0.1 unit/mL of thrombin (B). A 
concentration-inhibition curve for 2APT on 
collagen calculated with data shown here 
in Figure 3Ai can be found in Figure 6Ai. 
WT (i) and NOX1−/− (ii) platelets were 
tested following treatment with 2APT for 
10 minutes (0, 0.03, 0.1, 0.3, 0.3, 1 and 3 in 
Ai, and 0, 1 and 10 µM in Aii, Bi and Bii). 
Data from 4 independent experiments are 
shown on the right, while representative 
aggregation curves are shown on the left. 
Statistical analysis was performed by one-
way ANOVA with Bonferroni post-test 
(* for P < .05, ** for P < .01, *** for 
P < .001, ns for non-significant)
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F I G U R E  5  2APT derivatives inhibit aggregation and static adhesion of human platelets in response to collagen. Human washed platelets were 
resuspended at 2 × 108 cells/mL for aggregation experiments or 2 × 107 cells/mL for adhesion experiments. Platelets were incubated 10 minutes 
with 10 µM 2APT, 2APT-D1, 2APT-D2, 2APT-D3, 2APT-D4, 2APT-D5, 2APT-D6, 2APT-D7, 2APT-D8 or 2APT-D9. Aggregation was induced 
by 3 μg/mL of collagen (A, representative left and quantification right, n = 4). Static adhesion on collagen-coated surfaces in the presence of 2APT 
and derivatives was tested by fluorescence microscopy and quantified for area coverage. After initial testing of all derivatives at concentration 
10 µM, only 2APT, 2APT-D5, 2APT-D6, 2APT-D8 or 2APT-D9 were studied at lower concentrations (1 µM and 100 nM). Representative 
micrographs are shown on the left, while the quantification of the results is shown the right. Data were normalized to the control value in the 
absence of NOX1 inhibitors and expressed as % of surface area coverage in the absence of inhibitors. For the entire figure, n = 4 and statistical 
analysis were analyzed by one-way ANOVA with Bonferroni post-test (* for P < .05, ** for P < .01, *** for P < .001, ns for non-significant)
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was similar to wild-type controls for both carotid occlusion 
and tail bleeding.
NOX1 selectivity of 2-acetylphenothiazine (2APT) was 
then confirmed using electron paramagnetic resonance (EPR) 
spectroscopy.14 The calibration curve utilized to quantify 
the superoxide anion output is shown in Figure S1. In these 
experiments, 2APT significantly inhibited the superoxide 
anion generation induced by collagen on wild-type platelets, 
but not in NOX1−/− platelets (Figure  3A). The superoxide 
anion generation in response to thrombin was also inhibited 
by 2APT, although 1 µM was only marginally effective com-
pared to 10 µM (~25% inhibition vs ~80%, Figure 3B). The 
F I G U R E  6  Characterization of 
2APT-D6 by superoxide anion formation 
assays. For EPR experiments, mouse 
platelets were isolated from NOX1−/− and 
WT mice (C57BL6/J) and resuspended at 
2 × 108 cells/mL. Superoxide anion output 
was measured by EPR following platelet 
activation with 3 µg/mL of collagen (A) or 
0.1 unit/mL of thrombin (B) and measured 
for 10 minutes. Platelets were pretreated 
with 0, 1 or 10 µM 2APT for 10 minutes. 
The amount of oxidized CMH was 
quantified as described in the Methods and 
in Figure S1 and expressed as attomoles of 
CMH oxidized per platelet per minute. Data 
analysis from 4 independent experiments 
is shown, while representative EPR traces 
are shown in top panels. Statistical analysis 
was performed by one-way ANOVA with 
Bonferroni post-test (* for P < .05, ** for 
P < .01, *** for P < .001, ns for non-
significant)
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F I G U R E  7  2APT and 2APT-D6 inhibit aggregation in a NOX1- and GPVI-manner in mouse and human platelets. Platelet aggregation 
was stimulated with 3 µg/mL of collagen (A) or 1 µg/mL of CRP-XL (B and C). WT (Ai) and NOX1−/− (Aiii) mouse platelets were tested by 
turbidimetry following treatment with 2APT-6 for 10 minutes (0, 0.03, 0.1, 0.3, 0.3, 1, 3 or 10 µM). Concentration-inhibition curves for 2APT-D6 
and 2APT (from data in Figure 3Ai) in WT mouse platelets are shown in Aii. In addition, 2APT-D6 and 2APT were tested for their effect on WT 
mouse (B) and human (C) platelet aggregation induced by 1 µg/mL of CRP-XL. Representative examples from 3 independent experiments and 
their quantification are shown. The aggregation values at 9 minutes were fitted to a variable slope sigmoidal concentration-response to obtain IC50 
values for 2APT and 2APT-D6 (in red and green, respectively). Statistical analysis was performed by one-way ANOVA with Bonferroni post-test 
(* for P < .05, ** for P < .01, *** for P < .001, ns for non-significant)
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inhibitory effect at 10 µM 2APT was detectable in NOX1−/− 
platelets stimulated by thrombin (Figure 3B).
2APT was shown to inhibit collagen-dependent aggrega-
tion of wild-type platelets in a concentration-dependent man-
ner (Figure 4Ai), while the effect in NOX1−/− was apparent 
only at 10 µM (Figure 4Aii). Moreover, thrombin-dependent 
aggregation in wild-type and NOX1−/− platelets was only 
marginally affected by 2APT and only at the highest concen-
tration (10 µM) (Figure 4Bi,ii).
In order to improve 2APT selectivity (by increasing the 
potency of NOX1 inhibition) and bioavailability (by in-
creasing the hydrophilicity of the drug), a group of synthetic 
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derivatives was synthesized and examined in this study 
(2APT-D1/9). The nine derivatives are in Figure 1 (including 
their calculated hydrophobicity cLogP) and their syntheses 
are described in the Supplementary Methods. All nine newly 
synthesized compounds were tested in platelet aggregation 
experiments, where only 2APT, 2APT-D5, 2APT-D6, 2APT-
D8, and 2APT-D9 inhibited responses induced by 3  µM 
collagen, while 0.1 unit/mL of thrombin was not affected 
(Figure 5A and Figure S3A, respectively). Similarly, a static 
platelet adhesion assay on collagen confirmed the activity of 
2APT-D5, 2APT-D6, 2APT-D8, and 2APT-D9 (Figure 5B). 
The active derivatives 2APT-D5, 2APT-D6, 2APT-D8, and 
2APT-D9 were further tested by static adhesion onto collagen 
at a concentration of 1 μM and 100 nM, at which only 2APT-
D6 significantly inhibited platelet adhesion (Figure 5B). In 
parallel, neither 2APT nor its derivatives inhibit platelet ad-
hesion to fibrinogen (Figure S3B).
Using EPR, we found that: (1) 2APT-D6 at a concen-
tration of 1 or 10  µM reduces superoxide anion formation 
in response to collagen extensively (Figure 6A); (2) NOX1 
specificity cannot be tested in NOX1−/− platelet stimulated 
by collagen as the agonist-induced superoxide generation is 
absent (Figure 6A); (3) the inhibition of superoxide genera-
tion in response to thrombin is significantly higher for 10 µM 
than 1  µM 2APT-D6 in wild-type mouse platelets (~85% 
inhibition vs ~50%, Figure  6B); (4) only 10  µM but not 
1 µM 2APT-D6 has a minor inhibitory effect on thrombin- 
dependent superoxide generation in NOX1−/− (Figure 6B).
In aggregation assays, 2APT-D6 inhibited collagen- 
induced WT mouse platelet aggregation in a concentration- 
dependent manner (Figure  7Ai), with higher potency than 
2APT (IC50 = 52 ± 18 nM vs 141 ± 42 nM, Figure 7Aii). 
NOX1−/− platelets were tested resulted insensitive to 2APT-D6 
except for the highest concentration of 10 µM (Figure 7Aiii). 
Both 2APT-D6 and 2APT inhibited mouse platelet aggre-
gation induced by the GPVI-selective agonist CRP-XL,35 
with IC50 of 77  ±  24  nM and 179  ±  37  nM, respectively 
(Figure 7B). CRP-XL aggregation experiments were repeated 
on human platelets, confirming higher potency for 2APT-D6 
over 2APT (145 ± 25 vs 383 ± 5 nM, Figure 7C).
Either 2APT-D6 or 2APT inhibited collagen-dependent 
thrombus formation underflow, although a significantly 
higher inhibition was detected for 2APT-D6 at 100 nM com-
pared to 2APT (Figure 8A). Integrin αIIbβ3 activation and 
P-selectin externalization (ie, degranulation) in response to 
3 µg/mL of CRP-XL were also inhibited by both 2APT-D6 
(blue symbols) and 2APT (red symbols) (Figure 8Ci,Di, re-
spectively). Notably, 2APT-D6 appeared significantly more 
effective at 0.1 µM than 2APT (red connector lines and as-
terisks). Both activation of αIIbβ3 and P-selectin external-
ization in response to 1 unit/mL of thrombin were inhibited 
only by the highest tested concentration for both compounds 
(ie, 10 µM, Figure 8Cii,Dii, respectively).
The compounds were then administered in mice via the 
diet by mixing ground chow diet pellet with drug solution (in 
2% v/v dimethyl sulfoxide) in order to obtain a daily dose of 
20, 60 or 200 mg/kg. After two full days of treatment, washed 
platelets were tested by EPR, which showed significant in-
hibition of collagen-dependent superoxide generation, while 
the thrombin-dependent superoxide output was not affected 
(Figure 9A). In parallel, washed platelet turbidimetry showed 
that both compounds comprehensively inhibit collagen- 
dependent aggregation (Figure  9Bi), but have no effect on 
thrombin-dependent aggregation (Figure 9Bii).
Whole blood from mice that received the compounds 
orally was tested for thrombus formation on collagen in 
the absence of coagulation and under physiological flow 
(1000 sec−1). Either 2APT or 2APT-D6 at 200 mg/kg daily 
dose comprehensively abolished thrombus formation. 
When tested at different daily doses (60 and 20  mg/kg), 
2APT and 2APT-D6 showed a similar dose-dependence, 
with 25%-30% inhibition of thrombus formation by 60 mg/
kg and no effect by 20  mg/kg (Figure  10A). The induc-
tion of carotid occlusion by ferric chloride was also sig-
nificantly delayed by 200 mg/kg daily doses of 2APT- and 
2APT-D6 (Figure 10B), while no significant effects were 
F I G U R E  8  2APT and 2APT-D6 inhibit collagen-dependent thrombus formation, integrin αIIbβ3 activation, and P-selectin externalization. 
2APT and 2APT-D6 were compared in whole blood thrombus formation assays under shear stress (A). The compounds were incubated for 
10 minutes at concentrations 0.1, 1 and 10 μM on whole blood from human healthy volunteers where platelets were stained by DiOC6. The flow 
was applied for 10 minutes (1000 sec−1) before fluorescence pictures of the surfaces were taken to reveal the formation of thrombi. Representative 
examples for drug concentration 1 μM are shown in Ai, while statistical analysis for all drug concentrations is shown Aii (n = 6, one-way ANOVA 
with Bonferroni post-test, * for P < .05, ** for P < .01, *** for P < .001, ns for non-significant). For flow cytometry, platelets were isolated from 
human blood, resuspended at 2 × 107 cells/mL, and activated with 3 µg/mL of CRP-XL or 1 unit/mL of thrombin in static conditions. The platelet 
population analyzed by flow cytometry is shown in B (forward scattering vs side scattering plot, left panel). Integrin αIIbβ3 activation (B, central 
panel) and P-selectin externalization (B, right panel) were analyzed by staining with activated αIIbβ3 (PAC-1) and P-selectin antibodies followed 
by flow cytometry. Platelets were incubated 10 minutes with 0, 0.01, 0.1, 1 or 10 µM of 2APT or 2APT-D6 before stimulation and immunostaining. 
The effect of 2APT and 2APT-D6 on integrin αIIbβ3 activation (C) and P-selectin externalization (D) in response to CRP-XL (i) and thrombin (ii) 
is shown (mean ± SEM, n = 4). Statistical analysis was performed by one-way ANOVA with Bonferroni post-test, * for P < .05, ** for P < .01, 
*** for P < .001, ns for non-significant. Although results for 2APT and 2APT-D6 are similar, the effect of the compounds at concentration 0.1 µM 
is statistically different (2APT-D6 causes more extensive inhibition, red lines, and asterisk to indicate P < .05)
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F I G U R E  9  In vivo administration of 2APT and 2APT-D6 selectively inhibits collagen-dependent superoxide anion formation and platelet 
aggregation. The drugs were administered in food (daily dose = 200 mg/kg). Control animals only received vehicle solution mixed with their food 
(2% v/v DMSO). Superoxide anion formation in response to 3 µg/mL of collagen or 0.1 unit/mL of thrombin was measured for 10 minutes by EPR 
spectrometry (statistical analysis and representative examples are shown in A). Collagen- and thrombin-dependent aggregation were measured by 
turbidimetry (Bi and Bii, respectively). Representative example of aggregation curves are shown on the left and statistical analysis is shown on 
the right. Throughout this figure, statistical analysis was performed by one-way ANOVA with Bonferroni post-test (n = 4, * for P < .05, ** for 
P < .01, *** for P < .001, ns for non-significant)
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detected for the daily dose of 20 mg/kg (data not shown). 
Notably, tail bleeding time assays were not affected by 
treatment with either 2APT or 2APT-D6 even at the highest 
daily dose of 200 mg/kg (Figure 10C). Finally, using liq-
uid chromatography-mass spectrometry (LC-MS), 2APT 
was detected in plasma, kidney, and liver homogenates of 
C57BL6/J mice receiving the drug orally (Figure  10Di). 
C57BL6/J mice fed either 2APT or 2APT-D6 (200 mg/kg 
daily) showed detectable levels of 2APT but not 2APT-D6 
(Figure 10Dii). A novel 2APT-glucose adduct was detected 
in the platelet-rich plasma of C57BL6/J mice fed either 
2APT or 2APT-D6 (Figure 10Diii).
4 |  DISCUSSION
Using NOX1−/− and NOX2−/− transgenic mice29,30 and a 
model of carotid occlusion induced by ferric chloride,31 we 
proved that NOX1 accelerates thrombosis. In parallel, hemo-
stasis tested in tail tip transection assays36 is unaffected by 
NOX1 deficiency. NOX1 is, therefore, a promising target for 
the development of pharmacological agents able to protect 
against thrombosis without increasing bleeding risk. Using 
washed platelets from NOX1−/− and NOX2−/− transgenic 
mice, we have also proved that NOX1 is critical for collagen 
responses, while the latter is required for thrombin responses. 
This is in agreement with previous studies,10,13,14 but in con-
trast with other reports.9,37 This discrepancy is difficult to 
explain, although it can be at least partially explained with 
the differences in experimental tools and conditions utilized. 
For example, the inhibitor peptide used as NOX2-specific 
by Cammisotto and colleagues37 directly binds and competi-
tively inhibits p47phox.38 Therefore, in addition to inhibiting 
NOX2, this peptide can potentially inhibit the p47phox- 
dependent activation of other NOXs (including NOX139-41) 
and the results from this manuscript may be reinterpreted 
under a different light. Interestingly, our conclusions on the 
role of NOX1 in collagen signaling are in agreement with a 
recent paper showing no changes in platelet responses to col-
lagen in NOX2−/− mice and Cybb (NOX2)-mutation bearing 
granulomatous disease (CGD) patients.12
Our current data obtained with the GPVI-specific agonists 
CRP-XL are in agreement with previous literature suggesting 
a role for NOX1 in the regulation of the collagen receptor 
GPVI.10,13,14 Pharmacological inhibition of GPVI has been 
shown to reduce thrombotic responses without affecting 
hemostasis in a manner similar to what we observed for 
NOX1−/− and GPVI targeting has previously been proposed 
as a potential strategy for the prevention of atherothrombo-
sis.42 Because only peptides or antibodies with notable lim-
itations about pharmacokinetics and deliverability have so 
far been successfully utilized as GPVI inhibitors,43-45 this 
receptor remains an interesting drug discovery target. In this 
study, we investigated the possibility of targeting NOX1 and 
indirectly dampening GPVI signaling with small molecule 
inhibitors. A number of small molecule NOX inhibitors with 
isotype selectivity have recently been developed.19,21,46,47 
We previously described the effect of the NOX1-selective 
inhibitor 2APT on platelets ex vivo.10 Here we further char-
acterized the antiplatelet potential of 2APT both ex vivo 
and in vivo. In addition, in order to improve its water sol-
ubility and potency as NOX1 inhibitor (which would allow 
its use without the risk of reaching the threshold at which 
other NOXs are also affected), we designed, synthesized, and 
examined nine related chemical derivatives of 2APT. The 
2APT derivatives 2, 3, and 7 possess modifications to the 
2APT structure; however, the remaining derivatives all have 
the potential to release unmodified 2APT, via two different 
pathways. Specifically, derivatives 2APT-D1, 4, 5, 8, and 9 
can undergo hydrolysis to afford a common β-keto acid in-
termediate that can then undergo enzymatic decarboxylation 
to release 2APT.48 In an alternative approach, 2APT-D6 con-
tains a vinyl tert-butyl carbonate that upon hydrolysis is able 
to afford 2APT directly. A similar prodrug approach using 
a tert-butyl carbonate motif was examined with orally ad-
ministered entacapone and was reported to be quantitatively 
hydrolyzed to the drug in serum.49 Interestingly, the potency 
of the derivatives studied here seems unrelated to their hy-
drophilicity and water solubility, with the most potent deriv-
ative 2APT-D6 in vitro markedly less hydrophilic than 2APT 
(ie, cLogP 4.39 vs 3.93). It was promising to see that 2APT 
and 2APT-D6 orally administered to mice significantly re-
duced platelet responses (ie, aggregation, superoxide anion 
formation, and thrombus formation underflow—Figure  7). 
This suggests that the compounds that are not degraded in 
the GI tract, are absorbed and reach the blood at concentra-
tions compatible with their biological activity. 2APT could, 
in fact, be detected by mass spectrometry in kidney, liver, and 
platelet-rich plasma lysates of treated animals but not con-
trol animals that received vehicle solution (Figure 10D). The 
prodrug mechanism was confirmed by mass spectrometry 
experiments showing the parent molecule 2APT in animals 
treated with 2APT-D6. More surprising was the absence of 
2APT-D6 from the plasma of mice receiving this compound 
as treatment. This may suggest that only 2APT is retained in 
the bloodstream and is the active compound for both 2APT 
and 2APT-D6 treatments. It was, therefore, not surprising 
to see no potency difference between these two inhibitors in 
our in vivo experiments. At this point, we can hypothesize 
that because of its hydrophobicity, 2APT-D6 either does not 
reach the bloodstream or is readily cleared from it. In ad-
dition, a novel molecule appeared in the plasma of animals 
treated with 2APT and 2APT-D6, which was identified as 
a 2APT-glucose adduct. Further studies on the relevance of 
this molecule for absorption and biological activity of 2APT 
and 2APT-D6 are required.
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In summary, 2APT and 2APT-D6 selectively impair 
collagen-dependent activation of platelets via inhibition of 
NOX1 without affecting thrombin responses, which reduces 
thrombosis without attenuating hemostasis (Figure 11 for a 
schematic diagram). These compounds could, therefore, be 
developed into antiplatelet drugs without the unwanted side 
effect of increasing bleeding risks,50,51 which is an unre-
solved weakness of existing drugs. The collagen receptor 
GPVI has been suggested as a potential antiplatelet drug 
target, but only two inhibitors reached an advanced devel-
opment stage (ie, Revacept and ACT017).52 Therefore, the 
development of a small molecule drug targets GPVI and 
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can be administered orally will be a great advance in the 
antithrombotic field.
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F I G U R E  1 0  Administration of 2APT and 2APT-D6 reduces thrombus formation underflow and ferric chloride-induced carotid occlusion in 
vivo, but does not affect bleeding time in a tail tip transection assay. Drugs were administered in food (daily doses: 20, 60, and 200 mg/kg). Control 
animals only received vehicle solution mixed with their food (2% v/v DMSO). Whole blood thrombus formation under shear stress (1000 sec−1 for 
10 minutes) was measured by DiOC6 platelet staining and fluorescence imaging. Representative results for 200 mg/kg and quantification of the 
surface area coverage for all three doses are shown (A, n = 4). Carotid occlusion was tested in vivo using a ferric chloride injury model (B). The 
time required for complete occlusion was plotted for vehicle-, 2APT- and 2APT-D6-treated animals (n = 6, mean ± SEM). Confirmation of carotid 
occlusion was obtained by hematoxylin staining, of which representative examples are shown in the panel. The same treatments were assessed in a 
tail tip transection assays (C), in which the time required for full interruption of bleeding was recorded (n = 9, mean ± SEM). 2APT detection by 
LC-MS in organs and plasma of animals treated orally (D). 2APT detection in organ homogenates of C57BL6/J mice fed 2APT is shown in (Di, 
n = 4). 2APT detection in platelet-rich plasma of C57BL6/J mice fed 2APT, 2APT-D6 or vehicle solution (2% v/v DMSO) is shown in (Dii, n = 5). 
A novel 2APT-glucose adduct was also detected in the platelet-rich plasma of C57BL6/J mice fed 2APT or 2APT-D6 but not vehicle solution  
(2% v/v DMSO) (Diii, n = 4). 2APT was detected as [M]+ and [M + H]+ ions at 241.0556 and 242.0634 m/z, while 2APT-glucose was detected as 
[M]+ and [M + H]+ ions at 419.1033 and 420.1111 m/z. Statistical analysis was performed by one-way ANOVA with Bonferroni post-test (* for 
P < .05, ** for P < .01, *** for P < .001, ns for non-significant)
F I G U R E  1 1  Graphical interpretation of the data presented in this manuscript. 2APT and 2APT-D6 selectively inhibit NOX1 and collagen-
dependent platelet activation, while sparing thrombin responses. In vivo, this translates in the attenuation of thrombotic responses such as 
carotid occlusion depending on collagen-dependent platelet activation, while thrombin-dependent platelet activation guarantees sufficiently 
effective hemostasis as shown by unaffected tail bleeding time. 2APT = 2-acetylphenothiazine; 2APT-D6 = 2-acetylphenothiazine derivative 6; 
GPVI = glycoprotein VI; NOX = NADPH oxidase; PAR = protease-activated receptor
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